Evidence map›Paper›PMID 38335137›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2024

Testosterone Treatment, Weight Loss, and Health-related Quality of Life and Psychosocial Function in Men: A 2-year Randomized Controlled Trial.

Mathis Grossmann, Kristy P Robledo, Mark Daniel, David J Handelsman, Warrick J Inder, Bronwyn G A Stuckey, Bu B Yeap, Mark Ng Tang Fui, Karen Bracken, Carolyn A Allan and 3 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mathis GrossmannDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, VIC 3084, Australia.ORCID 0000-0001-8261-3457
Kristy P RobledoNHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW 2050, Australia.
Mark DanielDepartment of Population Health, Dasman Diabetes Institute, Kuwaiit City, Kuwait.
David J HandelsmanDepartment of Andrology, ANZAC Research Institute, University of Sydney and Department of Andrology, Concord Hospital, Concord, NSW 2139, Australia.ORCID 0000-0002-4200-7476
Warrick J InderDepartment of Endocrinology, Princess Alexandra Hospital and the University of Queensland, Woolloongabba, QLD 4102, Australia.
Bronwyn G A StuckeyKeogh Institute for Medical Research, Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital and Medical School, University of Western Australia, Western Australia, Woolloongabba, QLD 4102, Australia.
Bu B YeapMedical School, University of Western Australia and Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Nedlands, WA 6009, Australia.ORCID 0000-0002-7612-5892
Mark Ng Tang FuiDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, VIC 3084, Australia.
Karen BrackenNHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW 2050, Australia.
Carolyn A AllanSchool of Clinical Sciences at Monash Health and Faculty of Medicine, Nursing and Health Sciences, Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Monash University, Clayton, VIC 3168, Australia.
David JesudasonDepartment of Medicine, University of Adelaide, Adelaide, SA 5005, Australia.
Jeffrey D ZajacDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, VIC 3084, Australia.
Gary A WittertFreemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, SA 5001, Australia.ORCID 0000-0001-6818-6065

Funding

National Health and Medical Research Council
6 · The paper itself

Abstract

objectiveTo determine the effect of testosterone vs placebo treatment on health-related quality of life (HR-QOL) and psychosocial function in men without pathologic hypogonadism in the context of a lifestyle intervention. DESIGN, SETTING,

participantsSecondary analysis of a 2-year randomized controlled testosterone therapy trial for prevention or reversal of newly diagnosed type 2 diabetes, enrolling men ≥ 50 years at high risk for type 2 diabetes from 6 Australian centers.

interventionsInjectable testosterone undecanoate or matching placebo on the background of a community-based lifestyle program. MAIN OUTCOMES: Self-reported measures of HR-QOL/psychosocial function.

resultsOf 1007 participants randomized into the Testosterone for Type 2 Diabetes Mellitus (T4DM) trial, 648 (64%) had complete data available for all HR-QOL/psychosocial function assessments at baseline and 2 years. Over 24 months, while most measures were not different between treatment arms, testosterone treatment, compared with placebo, improved subjective social status and sense of coherence. Baseline HR-QOL/psychosocial function measures did not predict the effect of testosterone treatment on glycemic outcomes, primary endpoints of T4DM. Irrespective of treatment allocation, larger decreases in body weight were associated with improved mental quality of life, mastery, and subjective social status. Men with better baseline physical function, greater sense of coherence, and fewer depressive symptoms experienced greater associated decreases in body weight, with similar effects on waist circumference.

conclusionIn this diabetes prevention trial, weight loss induced by a lifestyle intervention improved HR-QOL and psychosocial function in more domains than testosterone treatment. The magnitude of weight and waist circumference reduction were predicted by baseline physical function, depressive symptomology, and sense of coherence.

Indexed as

Diabetes Mellitus, Type 2Quality of LifeTestosteroneWeight LossAgedHumansMaleMiddle AgedPsychosocial FunctioningTreatment OutcomeTestosteronetestosterone undecanoatepsychosocial healthquality of lifeT4DMtestosterone

Identifiers

PMID38335137
PMCPMC11244181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.